Brazil’s Lima & Pergher hit with FDA warning letter; import ban in effect

FDA sign

Brazil’s Lima & Pergher was hit with an FDA warning letter in the wake of a February inspection that found significant violations at the company’s manufacturing facility.

The regulatory agency’s warning letter, issued Aug. 25, cited poor quality control that resulted in adulterated drugs coming out of the plant located in Uberlandia within the state of Minas Gerais in Brazil.

Specifically, the agency said the drugmaker failed to perform microbiological testing on each lot of finished product and had no stability data to support expiration dates on its drugs.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Additionally, inspectors noted that the facility’s raw material qualification process was inadequate for its drug products.

The FDA also recommended that Lima & Pergher hire a qualified consultant to get their factory in order.

The agency placed the company on its import alert list in July, effectively banning the company from distributing its drugs in the U.S.

- check out the warning letter

Related Articles:
Teva, Mylan eye Pfizer’s Brazil unit 
Brazil funds dengue vaccine PhIII, report says


Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.